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looks quite different depending on one’s
perspective. From the aortic or ventricular
side, the AML clearly begins immediately
below the semilunar attachment, whereas
from the atrial side, because of the thick-
ness of the LA itself, the base of the
AML seems to be well below the attach-
ment of the aortic valve cusp. The muscle
of the LA essentially folds down over the
base of the AML.
Again we thank Drs Nezic´, Knezevic´,
and Borovic´ for their interest and welcome
the debate. What could be more fun than
spirited disagreement among colleagues!
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Reply to the Editor:
We appreciate Dr Ugurlucan’s comments
on the issue of mycotic aortic aneurysms
treated by endovascular approach. We be-
lieve that the endovascular stent graft is su-
perior in some ways to open surgical repair
for the treatment of mycotic aortic aneu-
rysms, especially in the emergency setting
for debilitated patients with critical aortic
segment involvement. In a recent published
literature review by Kan and colleagues,1
the endovascular treatment strategy was
noted to have 30-day and 2-year survivals
of 89.6% and 82.2%, respectively. To
date, however, there is still no level I evi-
dence to convince us that endovascular
treatment is the criterion standard for my-
cotic aortic aneurysm.
In Taiwan, the abdominal aortic stent
graft was approved by Department of Health
for clinical use only after July 2005, and the
thoracic stent graft was approved after No-
vember 2006. In our published article,2 pa-
tients were treated through 2006, before
the endovascular stent graft era in Taiwan.
Since 2006, we have performed endovascu-
lar stent graft placement in patients with rup-
tured mycotic aortic aneurysm. In our
preliminary data, there have been 4 patients
with ruptured mycotic abdominal and tho-
racic aortic aneurysms treated by the endo-
vascular technique. Of these, 1 patient
required a total visceral artery debranching
procedure for the ruptured suprarenal my-
cotic aneurysm simultaneously with the
stent graft placement. The pathogen is simi-
lar to our published database2 as nontyphoid
Salmonella. There was one in-hospital death
with new development of aortoduodenal fis-
tula. There was another death later than 30
days from the non–aneurysm-related cause
of uncontrolled septic shock. The other 2 pa-
tients require long-term oral antibiotic ther-
apy. There were no cerebral vascular events
or stent graft–related deaths among these 4
patients.
This seems to be a result comparable to
that of open surgical repair. We are still
not sure, however, whether for those with
aortoesophageal aneurysm, aortobronchial
aneurysm, or residual abscess in the image
study further de´bridement and elective
open surgical grafting will be necessary af-
ter stent graft placement, once the patient
condition has been stabilized. In addition,
for mycotic aneurysms involving the aortic
arch or visceral arterial segment, the hybrid
debranching procedure or fenestrated
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To the Editor:
We read with interest the article by Hsu and
Lin1 in which they retrospectively reviewed
their patients who received surgical treat-
ment for infected aortic aneurysms at the aor-
tic arch. Mycotic aortic aneurysm treatment
is a challenging issue. Since the beginning
of modern cardiovascular surgery, surgeons
have searched for better treatment options
because of the high mortality and morbidity
rates of the classic surgical methods. The au-
thors’ results also confirm this.1
With the increasing experience and re-
finements in graft technology, endovascular
grafts are frequently used in the treatment of1404 The Journal of Thoracic and Cardianeurysms at critical segments of the aorta,
such as thoracic and arch levels,2 and even
to the ascending aorta by means of hybrid
therapy or alone.3
On the other hand, although it seems com-
pletely opposite to the nature of the treatment
of infected aneurysms, endoluminal stent
grafting is also applied for the treatment of
mycotic aneurysms. Although the long-term
results are not presented, the short and mid-
term outcomes of this treatment modality
have been promising when compared with
conventional surgical techniques (ie, exten-
sive debridement and artificial graft replace-
ment or extra-anatomic bypass procedures).4,5
We believe that endovascular stent graft
repair of mycotic aortic aneurysms, espe-
cially at the critical segments of the aorta
and in debilitated patients, is an attractive al-
ternative option with lowmortality and mor-
bidity rates in the midterm. However, long-
term results are definitely required before
this becomes the standard therapy. It would
be helpful if the authors would have com-
mented on this issue in their article.
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